latest thought altern payment model cover name
rais pt
anticip final rule
propos radiat oncolog altern payment model ro-apm end
year earli howev recent remov ro-apm unifi
regulatori agenda left propos long-term agenda juli
expir date report weve seen state indic final
rule longer near-term prioriti believ industri player continu
prepar final rule time admittedli black box
experi chang could mean want time review comment
propos simpli doesnt want held specif near-term deadlin
ro-apm acceler industri toward hypofraction dont think
trend revers see littl impact near-term financi forecast result
addit recent assum coverag take
opportun detail updat thought three compani increas
price target use multipl month
revenu estim prior feel multipl remain reason sinc
growth outlook var ep revenu expect outpac larg
cap med-tech compani separ note today increas price
target use multipl month revenu
estim reiter neutral rate
hypofractionationth cat bag ro-apm propos call
full cours radiat therapi given far fewer visit use higher
radiat dose profit altern best fast implement
mandatori rule might led rush buy system capabl higher
dose treatment worst may result custom confus
penalti long term think potenti delay chang trajectori
hypofraction growth anyth pauseif onemay give smaller
compani like addit time educ potenti custom market
hypofraction capabl includ near-term order bolu
model investor may disappoint ro-apm
doesnt materi near-term catalyst potenti delay affect
near-term financi forecast
potenti impact compani believ varian market leader
broad product portfolio pois win major new system order
result ro-apm howev think final rule less stock
catalyst sinc compani expans larg driven high-
margin high-growth busi like softwar linac sale emerg
market hand might enjoy outsiz impact order
book trend toward hypofraction even system would
move co growth rate meaning higher mridian fit well
trend toward higher dose deliveri better accuraci higher
price point mri-guid compon think ro-apm
secondari growth driver
updat thought cover compani within radiat oncolog space
inc buy rais pt
continu see varian good long-term invest compani make progress top line growth
margin expans came away last month investor day impress varian made seri forward-
think invest rang technologiesfrom intervent radiolog big data analyt allow
compani remain leader
america oncolog gross order histor major metric investor think fixat
number could eventu lessen next coupl year servic revenu emerg market oncolog order gain
steam still remain import varian hit street target metric
think compani futur look bright immedi catalyst like etho growth acquisit well
sustain long-term driver like proton servic revenu penetr emerg market
updat model recent revis histor
varian rate buy price target base month non-gaap ep estim varian trade
comp group feel premium warrant sinc compani revenu ep grow
significantli faster rate comp group averag addit mid-to-long-term outlook var revenu ep
conserv manag five-year expect make higher valuat multipl palat
risk rate price target includ halcyon adopt chang oper margin capit spend slowdown
hospit govern new competit healthcar multipl gener trade lumpi quarterli result
question fund way think investor readi embrac continu
like mridian technolog view best mr-guid radiat therapi option avail hearten
news collabor elekta ektaf rate buy pt zimmerman seem
indic softer competit landscap interest major player outsid radiat oncolog
howev want underscor possibl futur quarterli volatil either order revenu weve
seen recent quarter capit equip alway lumpi busi magnifi compani rel
small sell high-pric system one system fall order book recogn revenu easili mean
sizabl beat miss quarterli earn report like remain biggest near-term catalyst
companytickerr ptpricemarket cap bntm johnsonjnjnot pt pt bdxnot pt scientificbsxbuy pt factset data btig estimatespr ex-amortev/salescagr
rate buy price target base month revenu estim account
anticip cash dilut relat decemb financ multipl ntm revenu multipl
fast-grow med-tech comp group think realist reflect potenti inconsist order sale
howev look detail announc industri collabor may hold potenti higher order
revenu growth risk rate price target includ competit order volum abil convert order revenu
system fall backlog mri rt adopt long-term clinic data product delay high oper expens litig
 reimburs
believ view mani radiat oncologist best-in-class technolog cyberknif
radixact compani offer potenti custom sbrt imrt capabl recent forthcom upgrad
enabl system deliv treatment faster view faster treatment time necess order
compet radiat oncolog compani sinc patient throughout import clinician
workflow profit
like strateg decis past year includ china joint ventur compani vocal
education/market effort around ro-apm see china major catalyst horizon
model think could upsid particularli year
improv consist report revenu order dismay appar lack
investor interest stock trade ntm revenu estim think investor wari may stem
combin rel low growth compani size potenti lumpi quarter
mind think coupl factor could awaken investor interest includ emerg
potenti acquir compani acceler out-performance chines order revenu meaning
increas top line growth
rate neutral trade signific discount mid-cap comp group use small cap due
similar growth remain neutral given lumpi order revenu believ share begin
see meaning multipl expans compani must show depend higher revenu order growth
ntm surgicalisrgneutr inc ingnnot technologiesirtcbuy entxentneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
btig provid price target neutral-r stock risk rate includ order volum abil convert
order revenu system fall backlog potenti dilut product delay reimburs
ntm entm eepsrevsresmedrmdnot factset data btig estimatespr ex-amortcompanytickr ptpricemarket cap
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discont op non-control non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
incom product servic total y/i other- total cost gross sell gener total oper incom loss incom pre-tax incom incom taxes- net incom non-controlling net incom loss share marginsgross net oper expensenananananananananananananananananananananaep growthnananananananananananananananananananananasourc btig estim compani report
revenu egross y/i y/i y/i y/i y/i y/i y/i unit product servic gmnananananananananananananananananananananatot total btig estim compani report
accuray incom product servic total y/i total cost gross sell gener total oper incom loss incom pre-tax incom incom equiti incom loss jv- net incom non-controlling net incom loss dilut share sbc other- adj marginsgross net mkting oper growthnanananananananananananananananananananananananasourc btig estim compani report
accuray revenu egross y/i y/i y/i y/i y/i y/i y/i product servic total btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
